ImmuCell Corporation (ICCC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ImmuCell Corporation stock (ICCC) is currently trading at $6.39. ImmuCell Corporation PE ratio is 28.81. ImmuCell Corporation PS ratio (Price-to-Sales) is 1.99. Analyst consensus price target for ICCC is $14.00. WallStSmart rates ICCC as Sell.
- ICCC PE ratio analysis and historical PE chart
- ICCC PS ratio (Price-to-Sales) history and trend
- ICCC intrinsic value — DCF, Graham Number, EPV models
- ICCC stock price prediction 2025 2026 2027 2028 2029 2030
- ICCC fair value vs current price
- ICCC insider transactions and insider buying
- Is ICCC undervalued or overvalued?
- ImmuCell Corporation financial analysis — revenue, earnings, cash flow
- ICCC Piotroski F-Score and Altman Z-Score
- ICCC analyst price target and Smart Rating
ImmuCell Corporation
📊 No data available
Try selecting a different time range
ICCC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · ImmuCell Corporation (ICCC)
ICCC trades 354% above its Graham fair value of $1.43, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
ImmuCell Corporation (ICCC) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
ImmuCell Corporation (ICCC) Key Strengths (1)
Paying $1.99 for every $1 of annual revenue
Supporting Valuation Data
ImmuCell Corporation (ICCC) Areas to Watch (8)
Earnings declining -63.40%, profits shrinking
Very thin margins with limited operational efficiency
Micro-cap company with very limited liquidity and high volatility
Low profitability relative to shareholder equity
Thin profit margins with limited profitability
Low institutional interest, mostly retail-driven
Fairly priced relative to book value
Solid revenue growth at 17.80% per year
Supporting Valuation Data
ImmuCell Corporation (ICCC) Detailed Analysis Report
Overall Assessment
This company scores 38/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 8.0/10) while 8 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (1.99) suggest the stock is attractively priced.
The Bear Case
The primary concerns are EPS Growth, Operating Margin, Market Cap. Some valuation metrics including Price/Book (2.03) suggest expensive pricing. Growth concerns include Revenue Growth at 17.80%, EPS Growth at -63.40%, which may limit upside. Profitability pressure is visible in Return on Equity at 6.61%, Operating Margin at 8.84%, Profit Margin at 6.23%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 6.61% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 17.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. EPS Growth and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ICCC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ICCC's Price-to-Sales ratio of 1.99x trades at a deep discount to its historical average of 7.1x (0th percentile). The current valuation is 87% below its historical high of 14.81x set in Jun 2011, and 0% above its historical low of 1.99x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for ImmuCell Corporation (ICCC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ImmuCell Corporation is a strong growth company balancing expansion with improving profitability. Revenue reached 28M with 18% growth year-over-year. Profit margins are thin at 6.2%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 661.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Earnings fell 63% YoY while revenue grew 18%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Margin expansion: can ImmuCell Corporation push profit margins above 15% as the business scales?
Debt management: total debt of 14M is significantly higher than cash (4M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ImmuCell Corporation.
Bottom Line
ImmuCell Corporation offers an attractive blend of growth (18% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ImmuCell Corporation(ICCC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.